Pharmaceutical stocks have traditionally been considered logical choices for dividend stocks; here, we look at one of the blue chips of the pharmaceutical world, selling at discounts to historical valuations, explains John Dobosz, editor of Forbes Dividend Investor.
New York-based Pfizer (PFE) is one of the world's largest biopharmaceutical companies that discovers, develops, manufactures, and sells medicines for humans and animals.
Celebrex, for treating arthritis, and Viagra, for erectile dysfunction, are two of Pfizer's best selling drugs. Other products are targeted at Alzheimer's disease, cardiovascular issues, depression, pain, respiratory ailments, and smoking cessation.
As blockbuster drugs lose patent protection, Pfizer must find new sources of growth to make up for the lower sales. What's encouraging is recent news from Merck (MRK) that it was working with Pfizer to develop new cancer drugs.
Revenue for 2014 is expected to dip 3% to $49.9 billion, with earnings inching higher by 2.3% to $2.27 per share. Earnings are expected to grow 12.9% for the year that just ended, with revenue up 15.7%.
Top 10 International Companies To Watch For 2015: Chevron Corporation(CVX)
Chevron Corporation, through its subsidiaries, engages in petroleum, chemicals, mining, power generation, and energy operations worldwide. It operates in two segments, Upstream and Downstream. The Upstream segment involves in the exploration, development, and production of crude oil and natural gas; processing, liquefaction, transportation, and regasification associated with liquefied natural gas; transportation of crude oil through pipelines; and transportation, storage, and marketing of natural gas, as well as holds interest in a gas-to-liquids project. The Downstream segment engages in the refining of crude oil into petroleum products; marketing of crude oil and refined products primarily under the Chevron, Texaco, and Caltex brand names; transportation of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car; and manufacture and marketing of commodity petrochemicals, plastics for industrial uses, and fuel and lubricant additives. It a lso produces and markets coal and molybdenum; and holds interests in 13 power assets with a total operating capacity of approximately 3,100 megawatts, as well as involves in cash management and debt financing activities, insurance operations, real estate activities, energy services, and alternative fuels and technology business. Chevron Corporation has a joint venture agreement with China National Petroleum Corporation. The company was formerly known as ChevronTexaco Corp. and changed its name to Chevron Corporation in May 2005. Chevron Corporation was founded in 1879 and is based in San Ramon, California.
Advisors' Opinion:- [By Claudia Assis]
Big Oil shares were higher as well, with Exxon Mobil Corp. (XOM) �shares up 0.3%. Chevron Corp. (CVX) �shares rose 0.5%, while shares of ConocoPhillips (COP) �advanced 0.9%.
Hot Blue Chip Companies To Buy Right Now: Visa Inc.(V)
Visa Inc., a payments technology company, engages in the operation of retail electronic payments network worldwide. It facilitates commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities. The company owns and operates VisaNet, a global processing platform that provides transaction processing services. It also offers a range of payments platforms, which enable credit, charge, deferred debit, debit, and prepaid payments, as well as cash access for consumers, businesses, and government entities. The company provides its payment platforms under the Visa, Visa Electron, PLUS, and Interlink brand names. In addition, it offers value-added services, including risk management, issuer processing, loyalty, dispute management, value-added information, and CyberSource-branded services. The company is headquartered in San Francisco, California.
Advisors' Opinion:- [By Amanda Alix]
A long-standing dispute between credit card issuers Visa (NYSE: V ) and MasterCard (NYSE: MA ) and the businesses that accept consumer payments via those instruments is heating up again, as a flurry of lawsuits filed on both sides over a prior settlement regarding interchange fees jump-start the hostilities all over again.
- [By Ben Levisohn]
Visa (V) gained 2.8% this week and Walt Disney (DIS) rose 2.7% to $80.31, to lead the Dow higher. Visa managed to gain despite sanctions being imposed on two Russian banks. Pepco Holdings (POM) surged 24% after it agreed to be purchased by Exelon (EXC) for $27.25 a share in an all-cash deal. Exelon dropped 1.2% this week. Energizer (ENR) jumped 17% after it said it would split itself into two companies.
Hot Blue Chip Companies To Buy Right Now: Colgate-Palmolive Company(CL)
Colgate-Palmolive Company, together with its subsidiaries, manufactures and markets consumer products worldwide. It offers oral care products, including toothpaste, toothbrushes, and mouth rinses, as well as dental floss and pharmaceutical products for dentists and other oral health professionals; personal care products, such as liquid hand soap, shower gels, bar soaps, deodorants, antiperspirants, shampoos, and conditioners; and home care products comprising laundry and dishwashing detergents, fabric conditioners, household cleaners, bleaches, dishwashing liquids, and oil soaps. The company offers its oral, personal, and home care products under the Colgate Total, Colgate Max Fresh, Colgate 360 Advisors' Opinion:
- [By James Well]
Analysts��Consensus Position on Pfizer
Thirteen analysts including those at TheStreet, Thomson Reuters/Verus, Goldman Sachs, J.P. Morgan, Barclays Capital, Morgan Stanley and Argus Research are optimistic about the performance of Pfizer going forward and, hence, reiterated a consensus buy recommendation at an average target price of $31.78 per share. Last Wednesday, analysts at Goldman Sachs removed Pfizer from Goldman�� conviction buy list (CL) where Pfizer has been since Aug. 9, 2011, and placed it on the buy list but raised its price target from $34 to $35 per share. Jami Rubin, an analyst with Goldman Sachs, claimed that Pfizer has gone up by 82.5% since being added to the CL as against 53.9% for the S&P 500 during the period and, therefore, there was the need to replace Pfizer with AbbVie at a price target of $60 because they claimed AbbVie has greater upside at this time.
Hot Blue Chip Companies To Buy Right Now: Apple Inc.(AAPL)
Apple Inc., together with subsidiaries, designs, manufactures, and markets personal computers, mobile communication and media devices, and portable digital music players, as well as sells related software, services, peripherals, networking solutions, and third-party digital content and applications worldwide. The company sells its products worldwide through its online stores, retail stores, direct sales force, third-party wholesalers, resellers, and value-added resellers. In addition, it sells third-party Mac, iPhone, iPad, and iPod compatible products, including application software, printers, storage devices, speakers, headphones, and other accessories and peripherals through its online and retail stores; and digital content and applications through the iTunes Store. The company sells its products to consumer, small and mid-sized business, education, enterprise, government, and creative markets. As of September 25, 2010, it had 317 retail stores, including 233 stores in the United States and 84 stores internationally. The company, formerly known as Apple Computer, Inc., was founded in 1976 and is headquartered in Cupertino, California.
Advisors' Opinion:- [By Andrew Tonner]
It's anyone's guess what smartphone superpower Apple (NASDAQ: AAPL ) is introducing at its upcoming product launches -- which are expected later this year -- although we have some very good ideas. We recently saw some more detailed information emerge from a very credible source. According to reports, Apple's iPhone is in for a massive overhaul. In the video below, Fool contributor Andrew Tonner tells investors what's important about this major tech storyline.
- [By Bryan Murphy]
Think patent wars are only being fought - and won - by consumer technologies like Vringo, Inc. (NASDAQ:VRNG) and Apple Inc. (NASDAQ:AAPL)? Think again. While the Vringo patent war with Google Inc. (NASDAQ:GOOG) and the Apple infringement case against Samsung may have been the world's highest-profile patent litigation conflicts (and most covered by the media), patent infringement claims and subsequent court cases have become just as common within the biotech world. Just ask Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) and Gilead Sciences, Inc. (NASDAQ:GILD)... two biotech names that are currently duking it out over patents that look nearly identical. Indeed, a coin toss may be just as fair of a way to decide who's right and who's wrong between Idenix and Gilead.
No comments:
Post a Comment